Sökning: WFRF:(Van Praet J) > (2020-2024) > COVID-19 in adult a...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05674naa a2201357 4500 | |
001 | oai:prod.swepub.kib.ki.se:153250547 | |
003 | SwePub | |
008 | 240913s2023 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1532505472 URI |
024 | 7 | a https://doi.org/10.3324/haematol.2022.2808472 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Marchesi, F4 aut |
245 | 1 0 | a COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA) |
264 | c 2022-05-12 | |
264 | 1 | b Ferrata Storti Foundation (Haematologica),c 2023 |
520 | a Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible. | |
700 | 1 | a Salmanton-Garcia, J4 aut |
700 | 1 | a Emarah, Z4 aut |
700 | 1 | a Piukovics, K4 aut |
700 | 1 | a Nucci, M4 aut |
700 | 1 | a Lopez-Garcia, A4 aut |
700 | 1 | a Racil, Z4 aut |
700 | 1 | a Farina, F4 aut |
700 | 1 | a Popova, M4 aut |
700 | 1 | a Zompi, S4 aut |
700 | 1 | a Audisio, E4 aut |
700 | 1 | a Ledoux, MP4 aut |
700 | 1 | a Verga, L4 aut |
700 | 1 | a Weinbergerova, B4 aut |
700 | 1 | a Szotkovski, T4 aut |
700 | 1 | a Da Silva, MG4 aut |
700 | 1 | a Fracchiolla, N4 aut |
700 | 1 | a De Jonge, N4 aut |
700 | 1 | a Collins, G4 aut |
700 | 1 | a Marchetti, M4 aut |
700 | 1 | a Magliano, G4 aut |
700 | 1 | a Garcia-Vidal, C4 aut |
700 | 1 | a Biernat, MM4 aut |
700 | 1 | a Van Doesum, J4 aut |
700 | 1 | a Machado, M4 aut |
700 | 1 | a Demirkan, F4 aut |
700 | 1 | a Al-Khabori, M4 aut |
700 | 1 | a Zak, P4 aut |
700 | 1 | a Visek, B4 aut |
700 | 1 | a Stoma, I4 aut |
700 | 1 | a Mendez, GA4 aut |
700 | 1 | a Maertens, J4 aut |
700 | 1 | a Khanna, N4 aut |
700 | 1 | a Espigado, I4 aut |
700 | 1 | a Dragonetti, G4 aut |
700 | 1 | a Fianchi, L4 aut |
700 | 1 | a Del Principe, MI4 aut |
700 | 1 | a Cabirta, A4 aut |
700 | 1 | a Ormazabal-Velez, I4 aut |
700 | 1 | a Jaksic, O4 aut |
700 | 1 | a Buquicchio, C4 aut |
700 | 1 | a Bonuomo, V4 aut |
700 | 1 | a Batinic, J4 aut |
700 | 1 | a Omrani, AS4 aut |
700 | 1 | a Lamure, S4 aut |
700 | 1 | a Finizio, O4 aut |
700 | 1 | a Fernandez, N4 aut |
700 | 1 | a Falces-Romero, I4 aut |
700 | 1 | a Blennow, Ou Karolinska Institutet4 aut |
700 | 1 | a Bergantim, R4 aut |
700 | 1 | a Ali, N4 aut |
700 | 1 | a Win, S4 aut |
700 | 1 | a Van Praet, J4 aut |
700 | 1 | a Tisi, MC4 aut |
700 | 1 | a Shirinova, A4 aut |
700 | 1 | a Schonlein, M4 aut |
700 | 1 | a Prattes, J4 aut |
700 | 1 | a Piedimonte, M4 aut |
700 | 1 | a Petzer, V4 aut |
700 | 1 | a Navratil, M4 aut |
700 | 1 | a Kulasekararaj, A4 aut |
700 | 1 | a Jindra, P4 aut |
700 | 1 | a Sramek, J4 aut |
700 | 1 | a Glenthoj, A4 aut |
700 | 1 | a Fazzi, R4 aut |
700 | 1 | a De Ramon-Sanchez, C4 aut |
700 | 1 | a Cattaneo, C4 aut |
700 | 1 | a Calbacho, M4 aut |
700 | 1 | a Bahr, NC4 aut |
700 | 1 | a El-Ashwah, S4 aut |
700 | 1 | a Cordoba, R4 aut |
700 | 1 | a Hanakova, M4 aut |
700 | 1 | a Zambrotta, GPM4 aut |
700 | 1 | a Zambrotta, G4 aut |
700 | 1 | a Sciume, M4 aut |
700 | 1 | a Booth, S4 aut |
700 | 1 | a Rodrigues, RN4 aut |
700 | 1 | a Sacchi, MV4 aut |
700 | 1 | a Garcia-Pouton, N4 aut |
700 | 1 | a Martin-Gonzalez, JA4 aut |
700 | 1 | a Khostelidi, S4 aut |
700 | 1 | a Grafe, S4 aut |
700 | 1 | a Rahimli, L4 aut |
700 | 1 | a Ammatuna, E4 aut |
700 | 1 | a Busca, A4 aut |
700 | 1 | a Corradini, P4 aut |
700 | 1 | a Hoenigl, M4 aut |
700 | 1 | a Klimko, N4 aut |
700 | 1 | a Koehler, P4 aut |
700 | 1 | a Pagliuca, A4 aut |
700 | 1 | a Passamonti, F4 aut |
700 | 1 | a Cornely, OA4 aut |
700 | 1 | a Pagano, L4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Haematologicad : Ferrata Storti Foundation (Haematologica)g 108:1, s. 22-33q 108:1<22-33x 1592-8721x 0390-6078 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:153250547 |
856 | 4 8 | u https://doi.org/10.3324/haematol.2022.280847 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy